The Swedish Melanoma Registry and Nordcan data show Sweden among the highest melanoma incidence countries in Europe. The literature attributes this to a combination of fair Fitzpatrick I-II phototype prevalence, intermittent intense UV exposure during summer holidays at lower latitudes, a long-standing sunbed culture (though now in decline), and effective dermatological surveillance that captures more cases.

Q: Does Melanotan-2 prevent melanoma?

No. There is no peer-reviewed evidence that Melanotan-2 prevents melanoma in humans. The published literature instead contains multiple case reports of nevus darkening, eruptive dysplastic nevi, and melanoma developing in MT-2 users (Cardones & Grichnik 2009; Langan et al. 2009; Paurobally et al. 2011; Hjuler & Lorentzen 2014). MT-2 is not approved for any therapeutic use anywhere in the world.

Q: What is the difference between Melanotan-2 and afamelanotide (Scenesse)?

Afamelanotide (marketed as Scenesse) is a more MC1R-selective linear analogue of alpha-MSH that received EMA approval in 2014 and FDA approval in 2019 for the very specific orphan indication of erythropoietic protoporphyria (EPP). Melanotan-2 is a non-selective MC1/3/4/5 receptor agonist that has never been approved for any therapeutic use and is sold worldwide only as a research compound.

Q: What does the dermatology literature actually recommend for primary melanoma prevention?

Established primary prevention measures with supporting trial evidence include broad-spectrum sunscreen use (Green et al., JCO 2011), avoidance of indoor tanning beds (Boniol et al., BMJ 2012; IARC Group 1 carcinogen), reducing intermittent intense UV exposure, and total-body skin examination at intervals appropriate to risk phenotype. None of this body of work supports pharmacological tanning as a prevention strategy.

In short: Sweden’s high melanoma rates are explained by phototype, intermittent UV, sunbed history and surveillance, not by missing tanning peptides. Melanotan-2 has no approved melanoma-prevention role. Peer-reviewed case reports link unregulated use to nevus changes. It remains a research compound only.

Key facts

Nordic melanoma incidence is high despite low home ambient UV (the “Nordic paradox”).

Primary prevention evidence centres on sunscreen, avoiding sunbeds and reducing burn patterns.

Afamelanotide (Scenesse) is approved only for erythropoietic protoporphyria, not cosmetic tanning.

Melanotan-2 is a non-selective research melanocortin agonist with no approved indication.

This article does not recommend human use of MT-2 for any purpose.

Sweden is one of the most studied countries for cutaneous melanoma. It is also where a synthetic melanocortin agonist like Melanotan-2 appears in conversation more than the published evidence justifies. Pale phototypes, dark winters and holiday UV create the cultural backdrop. This piece covers Swedish epidemiology, dermatology prevention evidence, and where MT-2 sits in melanocortin research once you leave forum posts for journals.

Up front. The claim that Melanotan-2 prevents melanoma is not supported by the published literature. The peer-reviewed record contains the opposite signal: case reports of nevus darkening, eruptive dysplastic nevi and melanoma diagnoses during MT-2 self-administration. MT-2 is a research compound, not a clinical prevention tool. This article does not recommend human use for any purpose.

1. The Swedish Melanoma Picture, in Numbers

The Swedish Melanoma Registry (SweMR), running since 1990 and covering essentially the entire population, makes Sweden one of the best-documented melanoma cohorts in the world. The headline numbers are striking enough on their own:

Sweden sits in the top tier of European melanoma incidence, with age-standardised rates that the Nordcan database (Engholm et al., Acta Oncologica ) has tracked rising steadily for four decades.

Lyth and colleagues ( Acta Dermato-Venereologica , 2017) documented continued increases in both thin and thick melanomas through the 2000s - a pattern that mixed-mode early detection alone cannot explain.

The Swedish Cancer Society’s 2020s reporting puts cutaneous melanoma among the fastest-growing cancers in the country, with annual incidence increases historically averaging around 4–5% per year in adults.

Mortality has risen more slowly than incidence, consistent with both earlier detection and a real underlying rise in disease burden.

For comparison, Australia and New Zealand are the only consistently higher-incidence countries; Sweden, Norway and Denmark form a Nordic cluster that punches far above its latitude.

2. Why Sweden? The Four Drivers in the Literature

The published epidemiology converges on a roughly four-part explanation for the Nordic paradox: high melanoma rates despite low ambient UV at home.

Driver What it is Representative evidence Phototype High prevalence of Fitzpatrick I–II skin (fair, freckles, burns easily, tans poorly) - the phenotype with the strongest melanoma association. Bliss et al., Int J Cancer , 1995; Olsen et al. pooled analyses across Nordic cohorts. Intermittent intense UV The classic “sunburn on holiday” pattern - long pale winters, then concentrated UV exposure at lower latitudes, often with episodic burns. Elwood & Jopson meta-analysis, Int J Cancer , 1997; Gandini et al. systematic review, Eur J Cancer , 2005. Indoor tanning (sunbeds) Strong historical sunbed culture in Sweden and Norway, particularly among women under 30. Now declining following regulation, but cohort effects persist. Veierød et al., JNCI , 2003 (Norwegian/Swedish Women’s Lifestyle & Health cohort); Boniol et al., BMJ , 2012 (meta-analysis); IARC Group 1 carcinogen classification, 2009. Surveillance density High dermatology access and a complete national registry catch more thin lesions, lifting recorded incidence. Lyth et al., Acta Derm Venereol , 2017; Swedish Melanoma Registry annual reports.

Note what is not on that list. There is no published claim that Sweden’s melanoma rate is high because Swedes lack pigment-stimulating peptides. The pathway runs the other way. Pale phototype marks lower population-level MC1R signalling efficiency. Established interventions target UV exposure, not pigment pharmacology.

3. What Primary Prevention Actually Looks Like in the Evidence

The dermatology community has converged on a fairly narrow set of primary-prevention interventions with supporting trial or cohort evidence:

Broad-spectrum sunscreen, used regularly. Green et al. ( Journal of Clinical Oncology , 2011) reported roughly 50% lower invasive melanoma incidence at 10-year follow-up in regular daily sunscreen users versus discretionary use (Nambour trial). It is one of the few randomised primary-prevention trials in the field. The result is now in national guidance, including in Sweden.

Avoiding indoor tanning. Boniol et al. ( BMJ , 2012) linked first sunbed exposure before age 35 to roughly 59–75% higher melanoma risk. A measurable share of European cases was attributed to sunbeds. That evidence underpins the IARC Group 1 classification and Swedish sunbed regulations.

Reducing intermittent intense UV exposure. The pooled cohort evidence shows it is the burn pattern, not just total UV dose, that drives melanoma risk - supporting behavioural advice around midday sun, shade, and clothing.

Risk-tailored skin surveillance. For Fitzpatrick I–II individuals with personal or family melanoma history or atypical nevi, total-body photography and dermoscopic surveillance shorten time-to-diagnosis of thin lesions. The Swedish dermatology guidelines have built this in.

None of the major position statements (Swedish, EADO, or the EU Code Against Cancer 4th Edition) recommend a pharmacological tanning agent for primary or secondary prevention. The literature is not silent on the question. It has answered it.

4. Where Melanotan-2 Actually Sits in the Melanocortin Research Landscape

Melanotan-2 (MT-2) is a cyclic lactam-bridged heptapeptide analogue of α-MSH. It was synthesised at the University of Arizona by Victor Hruby’s group ( Journal of Medicinal Chemistry , 1995). It is a non-selective agonist at MC1R, MC3R, MC4R and MC5R. Receptor pharmacology is well characterised. A clinical prevention role is not.

The closest regulated melanocortin product is afamelanotide (Scenesse), a more MC1R-selective linear α-MSH analogue. It received EMA approval in 2014 and FDA approval in 2019 for erythropoietic protoporphyria (EPP) only. It is not approved for cosmetic tanning, melanoma prevention or general fair-skin protection in any jurisdiction.

Melanotan-2, by contrast, has never been approved for any therapeutic indication anywhere. It is a research compound. The European Medicines Agency, the UK MHRA, and equivalent bodies across Scandinavia have issued public warnings about unregulated MT-2 use stretching back to 2008.

The distinction that gets blurred. Afamelanotide (Scenesse) is a regulated medicine for a specific genetic disease. Melanotan-2 is a research peptide sold as a laboratory reagent. They are related molecules, but they are not interchangeable, and the existence of the first does not validate human use of the second.

5. What the MT-2 Case-Report Literature Actually Shows

This is the part of the conversation that the “perfect tanning tool” framing omits. The peer-reviewed safety record for unregulated Melanotan-2 self-administration is short, but the signal in it points in a consistent direction:

Cardones & Grichnik , Pigment Cell & Melanoma Research , 2009 - reported eruptive dysplastic nevi and a melanocytic lesion concerning for melanoma in a user of an “Internet tanning peptide” later identified as MT-2.

Langan et al. , BMJ , 2009 and British Journal of Dermatology , 2010 - described darkening of nevi, new dysplastic nevi, and clinical concerns following MT-2 self-injection in case series.

Paurobally et al. , Dermatology , 2011 - melanoma in situ developing in a young MT-2 user.

Hjuler & Lorentzen , Clinical and Experimental Dermatology , 2014 - a Scandinavian case series of striking nevus changes during MT-2 use, directly relevant to the Nordic population we’re discussing in this article.

Habbema et al. , International Journal of Dermatology , 2017 - a comprehensive review of the “risks of unregulated use of α-MSH analogues”, summarising the dermatological, cardiovascular and neurological adverse events reported across the literature.

Ellis et al. , JAMA Dermatology , 2018 - review of MT-2 adverse events including melanocytic changes and systemic effects.

No single case report proves that MT-2 causes melanoma. Case reports are not built for that. Still, the body of work is clear on one point: MT-2 can darken existing nevi, has been linked to new atypical pigmented lesions, and has been temporally associated with melanoma diagnoses in dermatology case reports. That is not the safety profile of a prevention agent.

There is also a practical problem the literature flags repeatedly. MT-2 darkens existing moles. That can obscure the dermoscopic and photographic surveillance used in Swedish primary prevention. Change-over-time assessment becomes harder.

6. So Why Does the “Swedish Girls Use MT-2” Narrative Persist?

The underlying observation is partly true. Sunbed culture among young Nordic women was historically strong. The desire to tan in a low-UV country is a documented cultural pattern. MT-2 enters that conversation as a forum “shortcut.” What gets dropped is the published record: no approved use, plus a case-report safety signal that runs opposite to the marketing.

The honest reading of the Swedish data is the boring one. The same traits that raise Nordic melanoma risk (Fitzpatrick I–II phototype, burn pattern, indoor-tanning exposure, atypical nevi) make a non-selective melanocortin agonist a worse idea, not a better one. Trial-backed prevention remains daily sunscreen, avoiding indoor tanning and regular skin checks.

7. What MT-2 Is Useful For, in Research

MT-2 still has a legitimate research place in in vitro and preclinical melanocortin pharmacology. As a non-selective agonist with characterised pharmacokinetics and binding data, it is a benchmark tool for mapping MC1R/MC3R/MC4R/MC5R biology. It also sat on the medicinal-chemistry path toward FDA-approved bremelanotide (PT-141) for HSDD. That is the research value of the molecule. None of that translates to a recommendation for human pigmentation use.

8. The Honest Takeaway

Sweden’s melanoma rate is high for well-documented reasons that are unrelated to pigment pharmacology.

The interventions with actual trial evidence are sunscreen, avoiding sunbeds, reducing intermittent UV burns, and risk-tailored skin surveillance.

Afamelanotide (Scenesse) is a regulated MC1R-selective medicine approved only for erythropoietic protoporphyria. It is not a cosmetic tanning agent.

Melanotan-2 is a non-selective melanocortin agonist with no approved human use anywhere. The peer-reviewed safety record contains repeated case reports of nevus changes and melanoma diagnoses in users.

The legitimate role of MT-2 is as a laboratory tool for melanocortin pharmacology research, not as a tanning intervention.

Frequently Asked Questions

Why does Sweden have such high melanoma rates?

A combination of high Fitzpatrick I–II phototype prevalence, intermittent intense UV exposure on holidays, a long-standing sunbed culture (now in decline), and dense national surveillance through the Swedish Melanoma Registry. The Nordic countries collectively sit near the top of European incidence despite low ambient UV at home.

Does Melanotan-2 prevent melanoma?

No. There is no peer-reviewed evidence that MT-2 prevents melanoma in humans. Case-report literature (Cardones & Grichnik 2009; Langan et al. 2009–2010; Paurobally et al. 2011; Hjuler & Lorentzen 2014; Habbema et al. 2017) points the other way: nevus darkening, eruptive atypical nevi and melanoma diagnoses in MT-2 users.

What is the difference between Melanotan-2 and afamelanotide (Scenesse)?

Afamelanotide is a more MC1R-selective linear α-MSH analogue, EMA-approved (2014) and FDA-approved (2019) for the rare metabolic disease erythropoietic protoporphyria. Melanotan-2 is a non-selective cyclic heptapeptide agonist at MC1R/MC3R/MC4R/MC5R that has never been approved for any human therapeutic indication, anywhere.

What does the dermatology literature actually recommend for primary prevention?

Daily broad-spectrum sunscreen (Green et al., JCO , 2011), avoiding indoor tanning beds (Boniol et al., BMJ , 2012; IARC Group 1), reducing intermittent intense UV burns, and risk-tailored total-body skin examination. The Swedish, EADO and EU Code Against Cancer recommendations are aligned on these points and do not include any pharmacological tanning agent.

Is Melanotan-2 legal in Sweden?

Like in most European jurisdictions, MT-2 is not authorised as a medicine in Sweden. The Swedish Medical Products Agency (Läkemedelsverket) has issued public warnings about unregulated MT-2 use, in line with EMA and MHRA positions. Material supplied as a research reagent is sold for laboratory use only, not for human application.

What is Melanotan-2 actually useful for?

In a research setting, MT-2 is a well-characterised non-selective melanocortin receptor agonist used to probe MC1R/3R/4R/5R pharmacology in vitro and in preclinical animal models. It was historically the medicinal-chemistry stepping stone to bremelanotide (PT-141), the FDA-approved MC4R-selective agonist for HSDD. That is the legitimate research lane.

Selected References

Lyth J et al. Stage-Specific Direct Healthcare Costs and Survival in Patients with Cutaneous Malignant Melanoma. Acta Dermato-Venereologica , 2017.

Engholm G et al. NORDCAN - a Nordic tool for cancer information, planning, quality control and research. Acta Oncologica , 2010.

Veierød MB et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. Journal of the National Cancer Institute , 2003.

Boniol M et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ , 2012;345:e4757.

Green AC et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. Journal of Clinical Oncology , 2011;29(3):257–263.

Gandini S et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer , 2005;41(1):45–60.

IARC Working Group. A review of human carcinogens - Part D: radiation. The Lancet Oncology , 2009;10(8):751–752 (sunbed Group 1 classification).

Hruby VJ et al. Cyclic lactam α-melanotropin analogues with bulky aromatic amino acids at position 7. Journal of Medicinal Chemistry , 1995;38(18):3454–3461.

Cardones AR, Grichnik JM. α-Melanocyte–stimulating hormone-induced eruptive nevi. Pigment Cell & Melanoma Research , 2009.

Langan EA et al. Change in moles linked to use of unlicensed “sun tan jab.” BMJ , 2009;338:b277.

Langan EA et al. Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’? British Journal of Dermatology , 2010;163(3):451–455.

Paurobally D et al. Melanoma in situ in a patient using Melanotan. Dermatology , 2011;222(3):204–206.

Hjuler KF, Lorentzen HF. Melanoma associated with the use of Melanotan-II. Clinical and Experimental Dermatology , 2014.

Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of α-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology , 2017;56(10):975–980.

Ellis SR et al. Trends in dermatology-related Internet content. JAMA Dermatology , 2018.

European Medicines Agency. Scenesse (afamelanotide) Summary of Product Characteristics, 2014 (EU marketing authorisation).

U.S. Food and Drug Administration. Approval of Scenesse (afamelanotide) for erythropoietic protoporphyria, 2019.

Buy Melanotan-2 from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

Sweden, Melanoma & Melanotan-2: What the Research Actually Says